Marijuana Vaporizer Market Size 2021 | Top Key Vendors – Aphria, Grizzly Guru, Etain, Chart Industries, The Nug – Breakout Live – Breakout Live

Fort Collins, Colorado: A new informative report titled “Marijuana Vaporizer Market Size, Analysis and Forecast 2021-2027” was recently published by Reports Globe in its extensive database that helps shape the future of companies through informed business decisions. It provides a comprehensive analysis of various business aspects such as the impact of COVID-19 analysis, global market trends, recent technological advances, market share, size, and new innovations. In addition, this analytical data was compiled using data mining techniques such as primary and desk research. In addition, an expert team of researchers sheds light on various static and dynamic aspects of the Marijuana Vaporizer market.

The Marijuana Vaporizer Market Report provides an in-depth study of the expansion factors, potential challenges, diverse trends, and opportunities for the market participants to enable readers to fully understand the Marijuana Vaporizer market landscape. In addition to market share, inventory tracking and numbers, contact information, sales, capacity, production, price, costs, sales, and company profiles, the main manufacturers have been included in the report. The main objective of the Marijuana Vaporizer industry report is to provide important information on competitive positioning, current trends, market potential, growth rates, and alternative relevant statistics.

(Exclusive Offer: Flat 30% discount on this report)

Get | Download Sample Copy @

The report first introduced the fundamentals of the Marijuana Vaporizer market: definitions, classifications, applications, and market overview, product specifications, manufacturing processes, cost structures, raw materials, etc. The report analyzes the main conditions of the world’s local business taking into account item cost, benefit, capacity, production, supply, demand, development rate, and advertising estimate, etc. Review of speculative yield.

The Following Companies are Major Contributors to the Marijuana Vaporizer Market Research Report:

  • Aphria
  • Grizzly Guru
  • Etain
  • Chart Industries
  • The Nug
  • FGB Natural Products
  • Innokin

Marijuana Vaporizer Market Segmentation:

Based on Type

  • Chargeable Type
  • Battery Type

Based on Application

  • Personal Use
  • Medical Application

Based on the Region:

• North America (USA, Canada and Mexico)
• Europe (Germany, France, Great Britain, Russia and Italy)
• Asia Pacific (China, Japan, Korea, India, and Southeast Asia)
• South America (Brazil, Argentina, Colombia, etc.)
• Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria, and South Africa)

Request a Discount on the report @

Marijuana Vaporizer Market Report Comprises:

• Marijuana Vaporizer Market [Current market size forecast until 2027 with CAGR]
• Regional breakdown [North America, Europe, Asia-Pacific, South America, and the Middle East and Africa]
• Market Size Breakdown by Country [Major Countries With Significant Market Share]
• Breakdown of Market Size by Type of Product / Service – []
• Market Size by Application / Industry / End User – []
• Market share and turnover/turnover of the top 10-15 market participants
• If applicable, the production capacity of the main actors
• Market Trends – New Technologies / Products / Startups, PESTEL Analysis, SWOT Analysis,
• Porter’s Five Forces, etc.
• Price Development – Average pricing across regions
• Ranking by the brand of the most important market players in the world

The report examines the details of Global Marijuana Vaporizer Marketing and offers a detailed analysis of the various factors that promote or hinder the growth of the market. It relies on the most modern explanatory tools to measure openings by anticipating the actors. It also profiles the leading companies that work there and collects information about their income. Your item offers will be taken into account when deciding on the advertising department.

View market snapshot before purchasing @

Key Questions Covered In the Report

  • What is the total market value of the Marijuana Vaporizer Market report?
  • What would be the forecast period in the market report?
  • What is the market value of the Marijuana Vaporizer Market in 2021?
  • What is the Key Industry Leader’s opinion for Marijuana Vaporizer?
  • Which is the base year calculated in the Marijuana Vaporizer Market Report?
  • What are the key trends in the Marijuana Vaporizer Market Report?
  • What are the market values/growth % of emerging countries?
  • Which market holds the maximum market share of the Marijuana Vaporizer Market?

Table of Contents:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Request customization of the report @

Customization of the Report:

Please contact us if you would like more information about the report. If you have any special requirements and would like customization, please let us know. We will then offer the report as you wish.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [email protected]


Sarkari Results, Thrive Market Research

Florida House Panel To Weigh Pot Potency – CBS Miami

Tallassee (CBSMiami/NSF) – A Florida House panel Tuesday will take up a controversial bill that would make changes in Florida’s medical-marijuana laws, including limiting the amount of euphoria-inducing THC in marijuana products.

The House Professions & Public Health Subcommittee is scheduled to consider the proposal (HB 1455), filed by Rep. Spencer Roach, R-North Fort Myers.

READ MORE: Florida City Vaccination Site Overwhelmed After False Rumor It Had No Restrictions

A similar bill (SB 1958) was filed this week in the Senate by Estero Republican Ray Rodrigues.

The Senate has blocked similar proposals during the past two years, but Senate President Wilton Simpson, R-Trilby, has said he thinks many senators could support the proposal this year.

In part, Roach’s bill would place a 10 percent THC cap on smokable marijuana.

READ MORE: Miami-Dade PD Arrests 19-Year-Old Wanted For Deadly Triple Shooting

THC, or tetrahydrocannabinol, is the main psychoactive component of marijuana that makes users feel high.

Medical-marijuana advocates and industry officials are fighting the proposals, arguing caps would force patients to spend more money to achieve the same effects from their medical treatment.

Supporters of caps contend that high-potency marijuana has negative mental-health effects, especially on the developing brain.

MORE NEWS: Ultra Fans Holding Out Hope Musical Festival Returns In 2022

(©2021 CBS Local Media. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. The News Service of Florida contributed to this report.)

Cannabis firms aim high despite the legal haze – Mint

Ironically, it was at the behest of the US in 1985 that India clamped down on cannabis, which now continues to be tightly controlled in a land where it has been a part of ancient culture and ayurveda. Recently, the UN Commission on Narcotic Drugs removed cannabis from a list of dangerous substances, tacitly acknowledging that its addictive and harmful effects had been exaggerated. India’s backing of the UN reclassification has kindled hopes that the country will join the new global movement towards exploiting the medicinal and commercial potential of cannabis.

Despite the legal haze, cannabis startups have begun to take root in India.

Bombay Hemp Co. or Boheco, an early mover in this space, started out around nine years ago with clothes and fabric made from cannabis plant fibre and has expanded into making ayurvedic supplements and formulations for nutrition and pain relief.

Safer parts

The plant’s fibre and seeds don’t come under India’s Narcotic Drugs and Psychotropic Substances Act, because they have a low concentration of THC (tetrahydrocannabinol), which gives us a ‘high’. It’s the flowers that are high in THC and many other cannabinoids like CBD whose medicinal effects researchers are rediscovering. Cannabinoids can also be derived from the leaves, whose THC content is relatively lower. In India, the flowers as well as the plant’s resin, which produces charas or hashish, are deemed narcotic substances, and so is the plant as a whole. The leaves are all right—legally—if they are separated from the flowers and resin.

Cannabis has been an ingredient in ayurvedic formulations for aeons. So, the ministry of AYUSH, whose mandate is to promote indigenous alternative medicinal systems, does allow ayurvedic products to include cannabis, and ayurvedic doctors to prescribe such medicines. The catch is the makers have to rely only on leaves to avoid falling under the purview of narcotics.

All this constructs a complex maze for any startup brave enough to bet on the future prospects of cannabis products. “When we began, a lot of communication was required with the regulators,” says Jahan Peston Jamas, one of the seven co-founders of Boheco. “But we were one of the first companies to receive licences from the Madhya Pradesh government for hemp seed products as well as our leaf-based wellness and ayurvedic products.”

Through its local licensed partners, Boheco has been sourcing the leaves from excise departments that control cannabis plants which grow abundantly in the wild in many parts of India, especially the foothills of the Himalayas, the north-eastern states and the Western Ghats of Kerala. It has also been working closely with industrial hemp growers in Uttarakhand, the first state to legalize cannabis cultivation. Several other states have let research organizations start working on improving seeds and developing medicinal products as the stigma abates.

Entrepreneurs and labs the world over are in search of combinations of THC, CBD and other cannabinoids that produce health benefits, pain relief, or even safe recreation. In India, the idea of opening up cannabis for recreation remains taboo, but there’s growing interest in medicinal uses. The problem is that the cultivation of cannabis has been curbed so much that raw materials will have to be imported for any meaningful scaling.

Regulatory bottlenecks are the reason cannabis startups are yet to attract institutional venture capital in India, although angel investors have been laying early bets. For instance, Ratan Tata is among the backers of Boheco, which has raised $1.5 million in funding so far.


“I think the supply chain as well as end uses are complicated because of legalities. Secondly, I’m not sure of consumer demand, especially when the products are expensive,” says Jinesh Shah, founding partner of Omnivore, when asked why the agritech VC had made no bets on hemp startups yet.

It’s a domino effect of regulations. Hemp could probably be grown more economically at scale in Bihar or Madhya Pradesh, but it’s only Uttarakhand that is trying to work with traditional growers in the mountains, where transport, storage and scaling are more challenging.

One way to work on the supply side is to adopt a cooperative society model, taking a leaf out of the Amul dairy playbook. Himalayan Hemp, based in the Kangra region of Himachal Pradesh, has taken this approach in its attempt to promote the growth of indigenous hemp plants that have unique characteristics. Co-founders Haneesh Katnawer and Sonam Sodha became aware of the lack of support and low income of hemp growers while travelling in the Himalayas a few years ago. Sodha, who comes from a rural area of Kutch in Gujarat, empathized particularly with the women in the hills. This led to an epiphany: Why not make sanitary pads out of cannabis hemp fibre?

Hemp is resilient, moisture-absorbent and anti-bacterial, making it an ideal candidate. So, the duo roped in a National Institute of Fashion Technology, Ahmedabad, designer to create a hemp sanitary pad and this was the genesis of Himalayan Hemp, which got registered as a startup in 2018. It was incubated in the National Institute of Agriculture Marketing in Jaipur, which also provided a grant to develop, test and deploy the pads. “We would start by training one woman in a village to make the pad. Then we would form a cooperative society when more women joined in. We kept going like that from village to village,” recalls Katnawer. It has added other products, including an N95 mask made of hemp last year.

At the outset, it focused on forming cooperative societies of hemp artisans, because cultivation is complicated by regulations. Even though Uttarakhand has legalized it, only cannabis varieties with less than 0.3% THC can be grown. This is borrowed from US regulation defining industrial hemp and its products.

The US standard puts indigenous farming in other regions at a disadvantage because it will require genetically modified or tissue-cultured seeds. “We don’t support the current hemp cultivation policy in Uttarakhand, which sets a 0.3% THC limit because that means we will have to import the seeds instead of using the local variety of hemp. This is not farmer-friendly and it will affect our biodiversity,” says Katnawer.

Despite a long tradition, India has missed out on the benefits of cannabis because of myopic policies. Canada was one of the first to legalize cannabis. Not surprisingly, Canadian firms are among the top marijuana stocks on US bourses. Now, China, where hemp has grown for thousands of years, aims to push cultivation and dominate the global cannabis market.

Malavika Velayanikal is a consulting editor with Mint. She tweets @vmalu

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

No Signs of Cannabis Growth Slowing – New Cannabis Ventures

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.


Cannabis markets across North America are booming. This week we shared updates from BDSA on several mature and newer markets for January as well as data from Illinois for the month of February. Growth was strong across the board, with acceleration in California, which grew 28.6% from a year ago, and extremely vigorous gains from a year ago in the most mature markets of Colorado and Oregon, which increased 35.5% and 48.2%, respectively. Also, on Friday evening, Florida data revealed that the number of medical patients has surpassed 500K, or 2.3% of the entire population. In the most recent week, growth from a year ago was 55%.

Florida’s growth has been aided by the addition of telehealth last year and perhaps as well the recent introduction of edibles. Another factor may be population growth during the pandemic. The state doesn’t report revenue. Instead, it shares weekly data on units dispensed, which has grown substantially faster than the patient count. Year-to-date, medical cannabis units dispensed have increased by 84% compared to the same period a year ago, while flower sales have grown 139%. This marks a gain from Q4 for medical cannabis products, which grew 75% from the prior year. Flower sales were just ramping up in late 2019, and that growth has slowed from 189% but remains extremely strong.

As we think about how the rest of 2021 might play out across America, we are quite optimistic that the robust revenue growth will continue. Of course, each market is unique, and states will grow at different rates. We have some concern that overall per capita consumption rates could decline somewhat mid-year compared to a year ago due to heightened demand during the pandemic and non-recurring stimulus checks, but several factors are likely to overwhelmingly offset any potential slowdown in same-person consumption.

We think one of the biggest drivers of legal cannabis market growth is the shift from the illicit market. The pandemic proved to be very helpful on this front, as states which had previously not permitted delivery or curbside pickup did so, and this changed the market in a big way. Consumers can now order cannabis online the same way they order other goods, something the illicit market can’t match. The very solid growth in mature Western states, especially for flower, is a sign that the legal market is continuing to convert illicit market consumers.

New markets opening are another growth driver, and this year Arizona has already quickly permitted adult-use sales. New Jersey is ramping up its medical program and will add adult-use later this year. Virginia, which just began sales to patients in late 2020, will be continuing to roll out its medical program, and it will also be adding flower, which should boost demand.

Growth in markets that are already legal for adult-use can often be constrained at first, limited by not enough supply and/or not enough points of distribution. So, newly legal markets, like California, Illinois, and Michigan, all of which have had constraints, have the ability to exhibit strong growth for a sustained period of time as the infrastructure continues to come online. This can be the case in medical markets as well, like Pennsylvania.

For public companies, the recent uptick in M&A points to even faster growth than the organic growth rates the overall legal cannabis industry will generate. The deals being done appear to be very accretive to the acquiring companies, and we continue to expect substantial tuck-in acquisitions ahead in this highly fragmented industry.

The legal cannabis industry is in its early days, with new markets opening and existing ones continuing to ramp up as supply and distribution expands. Even in the most mature markets, there is ample evidence that legal operators are taking share from the illicit market as well. Look for the industry to continue to generate strong growth over the balance of 2021.

Invest in Leading Cannabis Companies
This week’s newsletter is sponsored by Global X

While federal prohibitions complicate the business landscape, it is still possible to invest legally in cannabis. The Global X Cannabis ETF (POTX) delivers exposure to a variety of publicly listed cannabis companies from around the world in a single trade. POTX is listed on Nasdaq and can be accessed from leading brokerage apps. Learn more by clicking the link above.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$12.5M per quarter.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.


Alan & Joel

Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter

CSIRO secures a licence to develop medicinal cannabis – Lab + Life Scientist

CSIRO secures a licence to develop medicinal cannabis

Under a newly acquired licence, CSIRO will support the burgeoning local cannabis industry and partner with local manufacturers to drive the development of cannabis therapeutics, in a move that is set to create new jobs in Australia.

CSIRO scientist Adjunct Professor Peter Duggan said the licence places CSIRO at the forefront of research into the development of new cannabis medicines, which should help people with a variety of conditions including multiple sclerosis and chronic pain.

“Around the world, researchers are exploring the potential for medicinal cannabis to help with conditions such as epilepsy and the nausea and vomiting associated with chemotherapy treatment, multiple sclerosis and chronic pain,” Prof Duggan said.

“We had been able to do early-stage work with cannabis, but the new licence will enable us to develop cannabis-derived cannabinoid medicines using innovative extraction, refinement and formulation techniques.”

CSIRO is currently the only independent research institute in Australia able to develop drug manufacturing protocols in the medicinal cannabis space. Its work is expected to bridge the gap between the growing of plants and the manufacture of medicines, with the researchers developing the manufacturing protocols and preparing the first prototype products before transferring the technology to manufacturers for large-scale production.

Peter Crock, CEO of medicinal cannabis company Cann Group and Chair of Medicinal Cannabis Industry Australia (MCIA), said there are over 20 medicinal cannabis companies currently listed on the ASX, and a growing number of licensed cultivators and manufacturers now in Australia.

“Cann Group has worked closely with CSIRO over the past three years and has been pleased with the results,” Crock said.

“With this independent licence CSIRO will be able to play a key role in helping establish a vibrant industry in Australia.

“Research that creates new and enhanced medical products and improves manufacturing processes is important if we want Australia’s medicinal cannabis industry to be competitive in a global market.”

The global market for medicinal cannabis is projected to be worth US$44 billion by 2024.

Image caption: The botanical extracts team at CSIRO will develop cannabis products in the laboratory.

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Van Meter man arrested after cannabis farm catches fire –

Ryan David Chrisinger, 42, of Van Meter was arrested Saturday on a charge of controlled substance violation.

A Van Meter man was arrested Saturday night after a fire broke out in his marijuana-growing operation in Van Meter.

Ryan David Chrisinger, 42, of 808 Elm St., Van Meter, was charged with a controlled substance violation.

The incident began shortly after 8 p.m. in the 800 block of Elm Street in Van Meter, where multiple agencies responded to a report of a structure fire.

According to court records, officers of the Van Meter Police Department “observed a marijuana-growing operation” in Chrisinger’s “detached garage, which had a bale of burning marijuana in it upon arrival.”

A search of the premises disclosed “marijuana plants, growing supplies and equipment along with other items,” according to court records.

Chrisinger is held in the Dallas County Jail in advance of an initial appearance in Dallas County District Court.

Chrisinger was convicted of possession of a controlled substance in 1996 in Polk County District Court. He was convicted of possession of a controlled substance in 2002 in Polk County District Court.

*A criminal charge is merely an accusation, and the defendant is innocent until and unless proven guilty.

A Disappointed Israel Adesanya Couldn’t Move the Needle on New Zealand’s Cannabis Vote: ‘Everyone Knows I Smoke’ – Sportscasting

Fans generally appreciate UFC fighters for their MMA skills, but they’re regular people too. Just like how Conor McGregor routinely donates to charitable causes, Israel Adesanya doesn’t mind getting political every now and then. Let’s look at why the UFC fighter supported New Zealand’s failed vote for cannabis reform. 

Israel Adesanya is not a stranger to weed

RELATED: Gary Payton Launched His Own Cannabis Business Because of His Mom

Like many young people, Adesanya knows weed. As Newshub reports, not only is he a frequent user, but he’s also an informed user. Just like millions of other people, he likes to get high every now and again just for fun. And, like other users, he’s also aware of the power of weed, and how it can make someone more relaxed or more aware of their surroundings among other things. 

That’s why it wasn’t particularly shocking when Adesanya threw his support behind New Zealand’s recent referendum on cannabis. As Newshub reported, the Nigerian-New Zealander said, “Everyone knows I smoke. Everyone knows I partake in the plant.” That being said, Adesanya, being an informed user, is well-aware that moderation is key. He said:

I don’t think it should be banned. Just be smart about it — in moderation with everything. I wouldn’t advise fighting while you’re high, but I wouldn’t advise fighting drunk either, unless you’re Jackie Chan in Drunken Master.

Lots of people smoke weed

RELATED: 5 Former Athletes Succeeding in the Marijuana Industry

Adesanya isn’t alone in terms of his openness about his cannabis use. As Newshub reported, many other UFC fighters routinely and regularly smoke weed, sometimes for fun, and other times to relax after a hard fight. Since most UFC fighters live and fight in the U.S., where weed is being decriminalized or legalized in many states, there are simply far too many weed-smoking UFC fighters to list.

Two of the most obvious, of course, are Nate Diaz and his brother, Nick Diaz. Both of the Diaz brothers are avid pot smokers, and in a way, they’ve both helped reshape the image of weed use in the UFC. In fact, very recently, the UFC has completely relaxed weed-related rules when it comes to drug testing. Before, fighters could get disqualified if they tested positive for cannabis use. But that’s no longer the case.

Like many other places that are reforming cannabis rules, New Zealand’s 2020 referendum would’ve completely legalized the plant. It would’ve also regulated it and taxed it like New Zealand already does with alcohol and similar substances.

The referendum barely failed to pass however

Israel Adesanya celebrates after defeating Yoel Romero in their UFC middleweight championship fight during UFC 248
UFC middleweight championship Israel Adesanya | Jeff Bottari/Zuffa LLC

As Newshub wrote, Adesanya reasoned that, since it’s entirely possible to get drunk and crash a car in New Zealand, there shouldn’t be a reason why it’s still illegal to smoke pot. On top of that, he also thinks that people’s fear of weed comes down to old stereotypes. Adesanya told Newshub, “What’s wrong with taxing it? It’s just propaganda that’s been passed down through generations and frankly, I’m sick of it.”

With that being said, Adesanya wasn’t alone in his fight. Many other famous New Zealanders advocated for the legalization of cannabis. However, like The Guardian reported, unfortunately, Adesanya’s efforts were not enough. In the end, the people of New Zealand narrowly voted down the idea. About 48% of New Zealanders voted yes for cannabis reform, while about 51% voted no.

These results aligned with polls, which showed a tight race in the months leading up to the vote. Adesanya is undoubtedly disappointed that his country failed to pass this landmark reform. However, since he frequently travels to the U.S., he can legally light one up in certain states.

Comment: Legal cannabis best bet to curb illicit suppliers | – The Daily Herald

By Vicki Christophersen / For The Herald

It’s been less than a decade since Washington voters led the nation in approving a new approach for cannabis.

By creating a legal, regulated and quality-controlled marketplace that generates hundreds of millions in tax revenue for critical public services, Washington embraced an alternative to the failed “War on Drugs.” Instead, we have proved that a system grounded in robust regulatory oversight that is continuously honed by what we learn in the marketplace is possible. Today, a majority of Americans have access to legal cannabis products for either medicinal or recreational use. But skepticism toward legal cannabis and rhetorical reflexes from another era continue to persist, ignoring the realities of the illicit marketplace, history and science.

A recent guest commentary published in The Herald suggested that legal cannabis — specifically, cannabis concentrates — is detrimental to the health of kids and that certain legal products should be banned. The cannabis industry unequivocally agrees that no minor should have access to or ingest products produced by the regulated marketplace. In fact, cannabis retail locations have the highest compliance rate for not selling to minors, exceeding even the high compliance rates of tobacco and liquor sales. The guest commentary, unfortunately, sets aside the safety track record of the regulated industry and the reality of one of the most heavily monitored cannabis systems in the country.

The illicit marketplace for cannabis concentrates, flower and other products was thriving before voters approved Initiative 502 in 2012 to legalize cannabis. And while that illicit marketplace has been undermined by the availability of safe and regulated cannabis, it still offers — as it did before legalization — high-potency cannabis concentrates produced in garages with no visibility into what is added into and pushed to the streets. We don’t have to look far for evidence of the ongoing dangers of the illicit market. In 2019, more than 1,000 people became sick from vitamin E acetate in specific cannabis vapor-related products, an ingredient prohibited in regulated products in Washington but produced and sold in the illicit market to unsuspecting consumers, nonetheless. The public health threat of products found on the illicit market are a continuing reminder that product bans are rarely effective and don’t contribute to solutions for what concerns those who are currently focused on THC.

The cannabis industry — licensed, vetted business owners and their employees — who produce, process, and sell legal cannabis, strives every day to not only invest in a viable marketplace but also partner with regulators, lawmakers and the public in upholding the safety of those products and working to keep them out of the hands of minors. Science and a cautious approach, appropriately, guides the decision-making for policymakers. It’s also why visitors to a regulated cannabis retail store will see a variety of products on the shelves, from pre-rolled joints to mints, tinctures, oils and concentrates. Visitors will always see clear labels describing the relative potency of each product, the details of which are all required by state regulations in part to help inform adult users, and the THC-content in each serving.

The legalization and regulation of cannabis has driven the development of this wide variety of products. More and more people rely on cannabis products (via CBD) for wellness effects, whether it’s arthritic knuckles, nausea or sleeplessness. For products that are developed for THC’s properties, purity and dosage matter most, and both are heavily regulated. Today, regulated products are tested, quality-controlled and tracked to the point where even a single edible chocolate can be traced back to the very plant it came from in a field or indoor facility containing thousands of plants. As an industry, we encourage additional scientific research so that products used by adults may find more safe and beneficial applications of the cannabis plant.

None of this is true in the illicit marketplace. We cannot rely on garage chemists and dealers driving around plastic baggies of weed and jars of concentrates to keep cannabis out of the hands of kids or responsibly regulate the contents of those baggies and jars. That’s why Washington approved a legal marketplace and it’s why the regulated industry will continue to be a partner in any conversations founded in science and earnestly endeavoring to uphold a safe, quality-controlled, taxed and regulated marketplace for cannabis.

Vicki Christophersen is the executive director of the Washington CannaBusiness Association, which represents licensed cannabis producers, processors, retailers and certified labs in the state. Its mission is to advocate on behalf of a safe, quality-controlled and regulated cannabis marketplace that keeps products out of the hands of minors.

Talk to us

Down to the wire for cannabis legalization – Albuquerque Journal

Copyright © 2021 Albuquerque Journal

SANTA FE – The clock is ticking on this year’s push to legalize cannabis for adult users in New Mexico, but backers’ hopes are far from extinguished.

A Senate committee did not take action Saturday on any of the four marijuana legalization bills assigned to it, as had been previously scheduled, instead opting to hold off on the bills so a group of legislators working on a compromise proposal could have more time.

“I remain confident that a solution can be found,” Senate Majority Leader Peter Wirth, D-Santa Fe, said in a Saturday interview. “This is a very big issue with a lot of moving pieces.”


Wirth voiced support for using a legalization bill passed Feb. 26 by the House, which would authorize commercial sales to begin in January 2022, as the basis for a compromise.

In large part, that’s because the legislation, House Bill 12, could be amended in the Senate and then advanced, which would avoid the need for House committees to vote on it again.

“If that happens, I’m confident we have the votes on the Senate floor to get it passed,” Wirth said.

But Senate changes to the House-approved bill could also set the stage for a high-stakes legislative conference committee in the final days of the session, in which appointed lawmakers from each legislative chamber would try to hammer out a compromise.

Sen. Jacob Candelaria, D-Albuquerque, sponsor of one of the cannabis legalization bills, said there is still “plenty of time” left in this year’s session, which ends March 20.

“I have full confidence that the Senate will get a bill back to the House; with some amendments but in more than enough time to get this bill to the governor’s desk,” Candelaria told the Journal. “Thousands of jobs and billions of dollars in economic activity are on the line.”

But there are several issues to be resolved, including plant count and license limits for cannabis producers.

And several Republicans have suggested they would not support the House-approved bill in its current form and prefer other approaches to cannabis legalization.

Sen. Cliff Pirtle, R-Roswell, sponsor of a cannabis legalization bill that would allow New Mexico cities and counties to decide whether dispensaries could be located within their boundaries, said he objects to the proposed tax rate – it could be higher than 20% – and regulatory framework of the House measure.

He also said he believes “social justice” provisions included in the House-approved bill, such as expungement for cannabis possession convictions and a community grant fund to pay for education and other outreach efforts, should be kept separate from the issue of cannabis legalization.

Pirtle said in a recent interview that he has not been part of the working group discussions, adding, “I would help them if I was included in (the talks).”

While New Mexico lawmakers debate the issue, other states are moving ahead with legalization measures, as Virginia is on the verge of becoming the 16th state to legalize recreational marijuana.

In New Mexico, the state already has a medical cannabis program with more than 100,000 enrolled members. In addition, Gov. Michelle Lujan Grisham signed into law a 2019 bill that made possession of up to a half-ounce of marijuana a civil offense punishable with a $50 fine.

While the governor also supports cannabis legalization, as long as legislation includes safeguards for children and medical cannabis users, she has not weighed in on which of the cannabis bills she prefers – at least not publicly.

But there are plenty of strong opinions to go around.

Ben Lewinger, executive director of the New Mexico Cannabis Chamber of Commerce, said the legalization bill should be simple and streamlined.

But he said most licensed medical cannabis producers would support the House-approved bill if amendments are added dealing with cannabis production limits and industry representation in the rule-making process.

“It’s not anti-free market; it’s just that with a new recreational program the state needs to be able to do that to protect small businesses,” Lewinger said, citing the experiences of Oregon and other states that have enacted production limits after legalizing cannabis.

Proposals to legalize recreational marijuana have made incremental progress at the Roundhouse in recent years but have ultimately stalled before reaching the governor’s desk.

While many supporters are still optimistic this could be the year for a green breakthrough, due in part to election-related changes in the Senate, the delays on moving a compromise bill forward could signal the complexities of the issue.

“I think a lot of obstacles … still very much exist,” Lewinger said.